Endeavor completes patient enrolment in trial of ENV-101

$ 29.50 · 4.8 (666) · In stock

Endeavor has concluded patient enrolment in a Phase IIa clinical trial of ENV-101 (taladegib) to treat idiopathic pulmonary fibrosis (IPF).